Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 7

1.
2.

Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial.

Bailey CJ, Gross JL, Hennicken D, Iqbal N, Mansfield TA, List JF.

BMC Med. 2013 Feb 20;11:43. doi: 10.1186/1741-7015-11-43. Erratum in: BMC Med. 2013;11:193.

3.

Targeting the kidney and glucose excretion with dapagliflozin: preclinical and clinical evidence for SGLT2 inhibition as a new option for treatment of type 2 diabetes mellitus.

Whaley JM, Tirmenstein M, Reilly TP, Poucher SM, Saye J, Parikh S, List JF.

Diabetes Metab Syndr Obes. 2012;5:135-48. doi: 10.2147/DMSO.S22503. Epub 2012 Jul 23.

4.

Effects of dapagliflozin, an SGLT2 inhibitor, on HbA(1c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy.

Rosenstock J, Vico M, Wei L, Salsali A, List JF.

Diabetes Care. 2012 Jul;35(7):1473-8. doi: 10.2337/dc11-1693. Epub 2012 Mar 23.

5.

Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial.

Ferrannini E, Ramos SJ, Salsali A, Tang W, List JF.

Diabetes Care. 2010 Oct;33(10):2217-24. doi: 10.2337/dc10-0612. Epub 2010 Jun 21.

6.

A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment.

Wilding JP, Norwood P, T'joen C, Bastien A, List JF, Fiedorek FT.

Diabetes Care. 2009 Sep;32(9):1656-62. doi: 10.2337/dc09-0517. Epub 2009 Jun 15.

7.

Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes.

List JF, Woo V, Morales E, Tang W, Fiedorek FT.

Diabetes Care. 2009 Apr;32(4):650-7. doi: 10.2337/dc08-1863. Epub 2008 Dec 29.

Supplemental Content

Loading ...
Support Center